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Treatment of non-small-cell lung cancer (NSCLC) might take into account comorbidities as an important variable. The aim of this
study was to generate a new simplified comorbidity score (SCS) and to determine whether or not it improves the possibility of
predicting prognosis of NSCLC patients. A two-step methodology was used. Step 1: An SCS was developed and its prognostic value
was compared with classical prognostic determinants in the outcome of 735 previously untreated NSCLC patients. Step 2: the SCS
reliability as a prognostic determinant was tested in a different population of 136 prospectively accrued NSCLC patients with a formal
comparison between SCS and the classical Charlson comorbidity index (CCI). Prognosis was analysed using both univariate and
multivariate (Cox model) statistics. The SCS summarised the following variables: tobacco consumption, diabetes mellitus and renal
insufficiency (respective weightings 7, 5 and 4), respiratory, neoplastic and cardiovascular comorbidities and alcoholism (weighting¼1
for each item). In step 1, aside from classical variables such as age, stage of the disease and performance status, SCS was a statistically
significant prognostic variable in univariate analyses. In the Cox model weight loss, stage grouping, performance status and SCS were
independent determinants of a poor outcome. There was a trend towards statistical significance for age (P¼0.08) and leucocytes
count (P¼0.06). In Step 2, both SCS and well-known prognostic variables were found as significant determinants in univariate
analyses. There was a trend towards a negative prognostic effect for CCI. In multivariate analysis, stage grouping, performance status,
histology, leucocytes, lymphocytes, lactate dehydrogenase, CYFRA 21-1 and SCS were independent determinants of a poor
prognosis. CCI was removed from the Cox model. In conclusion, the SCS, constructed as an independent prognostic factor in a large
NSCLC patient population, is validated in another prospective population and appears more informative than the CCI in predicting
NSCLC patient outcome.
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Guidelines for the treatment of non-small-cell lung cancer
(NSCLC) have been proposed and, although not universally
accepted, might contribute to the improvement of disease
outcome. They are particularly useful for patients who are not
eligible for clinical trials. The application of guidelines is a
milestone in epidemiological observation and knowledge of the
disease prognostic evolution. Daily practice, however, suggests that
comorbidities in the therapeutic decision, although not conven-
tionally defined, could be of paramount importance.
The awareness of prognostic determinants of NSCLC may be
important in both clinical trials and routine practice (Komaki et al,
1993; Charloux et al, 1997; Paesmans et al, 1997; Merrill et al,
1999). For clinical trials, stratification of randomisation on known
prognostic factors is an important part of procedure. In routine
practice, therapeutic decision might be influenced by the state of
prognostic variables (Komaki et al, 1993). Up to now, the most
widely accepted prognostic determinants of NSCLC are disease
stage and performance status (Brechot et al, 1996; Mountain,
1997). Several other features such as male gender, age older than 60
years, nonsquamous histologies have also been reported as
negative prognostic factors (Williams et al, 1981; Charloux et al,
1997). In order to define NSCLC prognostic factors, simultaneous
appraisal of eventual determinants could be carried out for a large
patient population.
Routine treatment of patients with lung cancer requires taking
into account smoking-related diseases, functional status and
comorbidities. The term ‘comorbidity’ refers to noncancer-related
physical and mental disorders that may also affect a patient
outcome and treatment safety. Comorbidity should be distin-
guished from functional status, because the latter is a measure of a
patient’s ability to perform daily activities or other tasks (Firat
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set al, 2002a). Comorbidities may prevent the physician from
delivering optimal therapy because of possible treatment-related
side effects. Furthermore, for cancer in the elderly, comorbidities
can have a major impact on survival (Extermann et al, 1998). As a
result, patients who are eligible for conventional lung cancer
studies generally meet ‘good general health criteria’ and represent
a small segment of the NSCLC patient population routinely treated
in cancer units. Moreover, several investigators in oncology
consider comorbidities as a criterion for noneligibility. Restrictive
eligibility criteria increase the certainty that any observed
differences are attributable to the treatment and not to the
confounding influence of comorbid diseases.
The prognostic significance of comorbidities, independent of
performance status and tumour stage, has been extensively
demonstrated in different types of cancer (Feinstein et al, 1977;
Wells et al, 1984; Clemens et al, 1986; Miller et al, 1992; Waldman
and Potter, 1992; Piccirillo et al, 1994; Satariano and Ragland,
1994; Piccirillo and Feinstein, 1996; Rochon et al, 1996; Pugliano
et al, 1997; Singh et al, 1997; Extermann et al, 1998) including lung
cancer (Feinstein and Wells, 1990; Firat et al, 2002a). Comorbid-
ities may explain in part the variability of survival observed for
example in stage I NSCLC, varying from 43 to 84%.
Alternatively, comorbid conditions have been evaluated using
clinical scores in longitudinal studies. The most widely used
clinical score is Charlson’s. The Charlson comorbidity index (CCI),
published by Charlson et al (1987) in 1987, was developed based
on a longitudinal study of 559 patients admitted to a medical
service during a 1-month period. Any disease or clinical condition
resulting in a relative risk of death greater than 1.2 was included in
the scale. A total of 19 conditions were found to influence
significantly survival and were given a weighted score based on the
relative mortality risk. The sum of the weighted scores of all of the
comorbid conditions present in patients was then scaled to
establish the CCI. The weighted index was tested for its ability to
predict mortality in a cohort of women with histologically proven
primary breast cancer. With each increased level of the
comorbidity index, there was a stepwise increase in the cumulative
mortality attributable to comorbid disease (Charlson et al, 1987).
We investigated the prognosis of a large NSCLC population
followed-up over a substantial period of time, simultaneously
assessing the aforementioned comorbidities together with classical
prognostic determinants. This study aimed at determining whether
or not the amalgamation of a new simplified comorbidity score
(SCS) and the work up of NSCLC patients would improve the
ability to predict prognosis and to compare this new score with the
CCI. A two-step methodology was used in order to achieve this
goal; firstly, a score elaboration step from a large database, used to
build the SCS as a prognostic variable; secondly, a score validation
step in which the SCS reliability was tested in an independent
population.
PATIENTS AND METHODS
Step 1: score generation
Patients In order to organise lung cancer care, we built in 1998 a
health network of cancer institutions following common guidelines
and willing to implement a prospective patient database (OncoLR).
This health network was geographically limited to five French
territorial divisions. One of the main end points was to describe
accurately the characteristics of patients treated for NSCLC and to
define their prognosis. In this multicentre prospective study, 735
consecutive patients were treated between January 1998 and May
2003 in the different institutions of the OncoLR health network.
All institutions were invited to input electronic case report
forms into a comprehensive database owned by the oncoLR health
network. Case reports extracted for this study were selected
pending on the following criteria: histologically proven and
previously untreated NSCLC. Consequently, patients suffering
from small-cell lung cancer and patients admitted for adjuvant
treatment (following surgery), second-line therapy or palliative
care following anticancer treatment failure were not eligible.
Histological subclassification was carried out according to the
World Health Organization (WHO) classification (World
Health Organization, 1982). Performance status was estimated
according to the Eastern Cooperative Oncology Group (ECOG)
(Zubrod et al, 1960) and the percentage of weight loss during
the previous 4 months was recorded. Staging was carried out
by exhaustive procedures according to the 4th edition of the Union
Internationale Contre le Cancer (UICC) tumour node metastases
(TNM) classification (Sobin et al, 1987), the American Thoracic
Society map of regional pulmonary nodes (Tisi et al, 1982) and the
new Mountain stage grouping (Mountain, 1997). The following
investigations were carried out: a clinical examination, a standard
chest roentgenography, a computed tomographic (CT) scan of
chest and upper abdomen, fibreoptic bronchoscopy, liver sono-
graphy and bone scanning. A mediastinoscopy was used to
establish nodal status in NSCLC patients without evident
haematogeneous metastatic disease and evidence of mediastinal
lymph node enlargement on chest CT-scan. A brain CT-scan was
performed routinely. The upper limits of normal values were as
follows: leucocytes: 10000ml
 1; platelets count: 400000ml
 1.
This part of the study aimed at generating a new simplified
comorbidity score using specific comorbidities definitions. Both
academic institutions and community hospitals were involved in
this pragmatic part of the study, and the complex CCI that requires
the assessment of a broad number of comorbidities was not
included in step 1.
Comorbidity item definition Cardiovascular comorbidity was
defined as the presence of one or more of the following: congestive
heart failure, ischaemic cardiopathy with or without myocardial
infarction, severe valvular cardiopathy, arrhythmia requiring
chronic treatment, history of cerebrovascular disease, hyperten-
sion and/or peripheral vascular disease. Respiratory comorbidity
was defined as the presence of one or more of the following:
history of tuberculosis, history of pleural effusion or pneumonia,
asthma, pulmonary embolism, chronic pulmonary insufficiency as
defined by a chronic hypoxemia less than 60mmHg and/or
chronic obstructive pulmonary disease (COPD) inducing a FEV1
less than 1.5l. Neoplasic comorbidities were defined as a previous
personal history of cancer, excluding basal cell carcinoma of the
skin and in situ carcinoma of the cervix. Renal insufficiency was
defined as a creatinine clearance lower than 60mlmin
 1
(calculated according to the Cockroft formula). Diabetes mellitus
was defined as diabetes treated with either oral hypoglycemics or
insulin. Alcoholism was defined as a daily consumption of more
than 80g of alcohol for men and 40g for women. Tobacco
consumption was defined as a lifelong consumption of an
equivalent of at least 100 cigarettes.
Item weighting and elaboration of the SCS The following
method was adopted in order to build the SCS: comorbidities
were tested as single variables in independent univariate analysis.
The relative risk of death was taken into account in order to
select and organise the variables to be tested in an initial
multiparametric survival analysis. Each variable was tested in the
multivariate analysis and the b coefficients were determined with
regards to the adjusted risk. As a result of this analysis, the major
comorbidities were tobacco consumption, diabetes mellitus and
renal insufficiency as described above. These three variables were
affected by the highest weightings (7, 5 and 4, respectively). Other
features included in the SCS were respiratory, neoplasic and
cardiovascular comorbidities and alcoholism. Those well-known
limiting factors in lung cancer management were affected by a
weighting of 1 (Table 1).
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sStep 2: score validation
The SCS reliability as a prognostic determinant was tested in a
different population of 136 NSCLC patients prospectively accrued
in our two university departments from September 2003 to June
2004. Eligibility criteria and pretherapeutic work-up were con-
ducted similarly to the step 1 patient population. Additional
variables tested were: haemoglobin level, blood lymphocytes count,
serum fibrinogen, sodium, calcium, proteins, albumin, alkaline
phosphatases, lactate dehydrogenase (LDH), Cyfra 21-1 and
neuron-specific enolase (NSE) levels. Finally, the CCI was
evaluated previous to any treatment.
Treatment
Treatment was conducted similarly for the two populations. A
medical panel composed of thoracic surgeons, chest physicians,
radiologists, radiotherapists and medical oncologists discussed the
case of each patient in order to design a treatment programme to
be submitted for patient’s approval. Particular attention was paid
to the agreement between each individual proposal and the
oncoLR guidelines (http://poumon.oncolr.org/public/thesaurus-
Poumon.asp).
NSCLC patients with stage I or II disease underwent surgery in
an attempt at complete resection. Patients suffering from
pathologically demonstrated N2 disease received cisplatin-based
neoadjuvant chemotherapy followed by surgery whenever possible.
Other patients with performance status p2 and distant metastases
(stage IV) or gross mediastinal involvement (stage IIIb and
unresectable stage IIIa) were treated when clinically possible by a
cisplatin-based chemotherapy. Radiotherapy was applied in locally
advanced stages according to a concomitant schedule (Furuse et al,
1995). Best supportive care, including palliative radiation-therapy
when needed, was proposed to patients with advanced stage and
poor performance status. Treatment was decided upon according
to clinical and routine biological findings and without knowledge
of the SCS, although some of the comorbidities were obviously
taken into account in therapeutic choice (eg poor respiratory
function and surgical contraindication). Hence, treatment was not
considered as a prognostic variable in this study.
Statistics
k coefficient of reliability (Snedecor and Cochran, 1956) and
McNemar test of symmetry (Armitage, 1971) were used to test the
concordance of the two comorbidity scales that is, CCI and SCS. A
P-value o0.05 was considered as significant.
Survival was defined as the time from database registration to
the date of death whatever the cause. For the step 1 population,
survival data were updated on 1 September 2003. At end point, 14
patients were lost to follow-up (1.9%). Median follow-up was 25.9
months (range 3.3–67.4 months) and 530 events were recorded.
For the step 2 population, survival data were updated on 14
January 2005 and none of the patients were lost to follow-up.
Median follow-up was 10.3 months (range 6.7–16.5 months) and
50 events were recorded.
Coding methods for the different variables depended on their
nature. Some of the variables were extensively described in the
literature, therefore the threshold was defined using previous
publications. Performance status was analysed according to two
classical modalities: PS 0–1 and PS greater or equal to 2 (Zubrod
et al, 1960). The effect of nodal status on prognosis was tested
according to the presence or the absence of mediastinal lymph
node involvement. The same coding regarding tumour status has
been adopted according to the new Mountain’s stage grouping
(stages I–IIIa vs stages IIIb–IV) (Mountain, 1997). Owing to the
fact that the OncoLR guidelines are based on stage grouping
according to the Mountain’s system rather than the detailed TNM,
we considered Montain’s stage grouping as the staging variable in
the Cox model. TNM was not introduced in order to avoid
statistical redundancy. For the biological variables, previously
published thresholds were used particularly for Cyfra 21-1 (Pujol
et al, 1993, 2001) and NSE serum levels (Jorgensen et al, 1996;
Pujol et al, 2001).
Probability of survival was estimated by the Kaplan and
Meier (1958) method. Single variable survival analyses was
assessed by means of the Wilcoxon and log-rank tests and
multivariate regression was assessed with Cox’s model (Cox,
1972; Andersen, 1991). The classical forward selection of
variable procedure was used. The variables to be tested in the
Cox model were selected using the results of univariate analyses,
that is, variables reaching at least a P level less than 15%. This
model was written after a Boolean coding of the significant
variables: categorical variables (such as performance status)
were transformed into binary variables (0: negative or 1: positive).
The number of levels of a Boolean variable needed to describe a
predictive factor is one less than the categories of that factor
inasmuch as its baseline level is defined by setting the value
of each of the Boolean variables at zero. The significance of the
effect of a given factor was assessed by determining whether
or not the coefficient assigned to one or more of its categories was
sufficiently different from zero. The proportional hazard assump-
tion for each of the selected variables retained in the final model
was initially checked by plotting the log cumulative baseline
hazard ratio. A P level of less than 0.05 was considered significant.
All tests were two-sided. Survival was analysed using the SAS
software package.
In the step 1 population, the above-mentioned procedure
identified eight variables as putative prognostic determinants to
be tested in the Cox regression hazard model whereas in the step 2
population the number of variables was 17. Therefore, the main
population complied with the current recommendation (Harrell
et al, 1985) insofar as the number of variables represented less than
10% of the total of observed events (530 deaths).
RESULTS
Step 1: score generation
Patient’s demography and disease characteristics are summarised
in Table 2. Most of the main characteristics of NSCLC were
retrieved particularly a median age of 62.5 years. The median
survival of the whole population was 12.7 months (95% CI, 11.2–
14). The 1- and 2-year survival rates were 51% (95% CI, 48–55%)
and 29% (95% CI, 26–33%), respectively.
Univariate analysis The univariate analysis (Table 3) showed
that patients affected by one of the following characteristics proved
to have a shorter survival in comparison with the opposite status
of each variable: male gender, age X70 years, performance status
X2, tumour status X3, nodal status X2, metastatic status (M1),
Table 1 The simplified comorbidity score and weighting of comorbid-
ities
Comorbidity Weighting
Tobacco consumption 7
Diabetes mellitus 5
Renal insufficiency 4
Respiratory comorbidity 1
Cardiovascular comorbidity 1
Neoplastic comorbidity 1
Alcoholism 1
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count 410000ml
 1, blood platelets count 4400000ml
 1,
current or former smoker, renal insufficiency and SCS greater
than 9.
Multivariate analysis The following variables were independent
determinants of a poor outcome (Table 4): weight loss X5%,
hazard ratio (95% confidence interval): 1.39 [1.12–1.73], stage
grouping: 2.46 [1.90–3.18], performance status: 1.33 [0.99–1.76]
and SCS: 1.36 [1.09–1.69]. Two additional variables did not
formally reach statistical significance level: age X70 years: 1.23
[0.98–1.54] (P¼0.08) and leucocytes: 1.23 [0.99–1.52] (P¼0.06).
As a control, the SCS was tested as a continuous variable and the
Cox model was run again with the same variables. In this model,
SCS was retained and affected by a 1.05 hazard ratio [1.02–1.08],
P¼0.002. Other variables were similar with nearly identical hazard
ratios.
Step 2: score validation
Patient population and disease characteristics are summarised in
Table 5 together with the main univariate survival results. Patient
population in steps 1 and 2 of this study shared similar
characteristic distributions in terms of main prognostic variables.
the 1-year survival rate was 59% and median survival was not
reached at the time of study analysis.
Concordance of two comorbidiy scales A statistical concordance
was observed between CCI and SCS (k coefficient of re-
liability¼0.288; Po0.00001; Table 5). There was a statistically
significant asymmetry (McNemar test of symmetry; P¼0.0008).
Univariate analysis The univariate analysis demonstrated a
significant shorter survival for patients presenting one of the
following characteristics in comparison with patients presenting
the opposite status (Table 6): age 470 years, performance status
X2, stage grouping IIIb–IV, weight loss X5%, leucocytes
410000ml
 1, nonadenocarcinomatous histology, alkaline phos-
phatase X104Ul
 1, high CYFRA 21-1 serum level, lymphocytes
o1000ml
 1, protein p64gl
 1, albumin o35gl
 1,
LDHX450Ul
 1, NSE 412.5ngml
 1, serum calcium
42.6mmoll
 1, anaemia, high fibrinogen level and SCS 49. In
addition, there was a trend towards a significant negative
prognostic effect for a CCIX3, platelets 4400000ml
 1 and a
serum sodium p135mEql
 1. Survival according to CCI and SCS
values are shown in Figures 1 and 2, respectively.
Multivariate analysis In the multivariate analysis, the following
variables were independent determinants of a poor outcome: stage
grouping, 9.03 [3.04–26.76], performance status, 2.92 [1.43–5.98],
histology, 2.58 [1.21–5.48], leucocytes, 4.74 [2.30–9.76], lympho-
cytes, 2.93 [1.19–7.22], LDH, 3.48 [1.66–7.33], CYFRA 21-1, 3.77
[1.80–7.89], SCS, 2.66 [1.33–5.30]. However, CCI was removed
from the Cox model. It is worth noting that SCS, as a new
prognostic determinant, appeared as efficient as stage grouping in
Table 2 Step 1 patients’ demography and disease characteristics
Variables No. of patients (%)
Total 735
Age (years)
Median7s.d. 62.5711.2
Gender
Male 589 (80)
Female 146 (20)
ECOG performance status
o2 606 (82)
X2 124 (17)
Missing data 5 (1)
T-stage
1–2 245 (33)
3–4 466 (63)
Missing data 24 (4)
N-stage
0–1 270 (37)
2–3 438 (60)
Missing data 27 (3)
M-stage
0 395 (54)
1 340 (46)
Stage grouping (Mountain)
Ia 9 (2)
Ib 35 (5)
IIa 1 (1)
IIb 48 (6)
IIIa 112 (14)
IIIb 181 (24)
IV 340 (46)
Missing data 9 (2)
Histology
Squamous cell carcinoma 273 (37)
Adenocarcinoma 345 (47)
Large cell carcinoma 105 (14)
Unspecified NSCLC 12 (2)
Weight loss (%)
o5% 392 (53)
X5% 220 (30)
Unknown 123 (17)
Blood leuccyte count
p10000ml
 1 435 (60)
410000ml
 1 233 (31)
Unknown 67 (9)
Blood platelets count
p400000ml
 1 541 (75)
4400000ml
 1 130 (17)
Unknown 64 (8)
Metastases
Adrenal gland 54 (7)
Bone 129 (18)
Liver 54 (7)
Lung 140 (19)
Brain 71 (10)
Other sites 36 (5)
Smoking status
Current smoker 384 (52)
Former smoker 255 (36)
Non smoker 73 (9)
Missing data 23 (3)
Table 2 (Continued)
Variables No. of patients (%)
Comorbidities
Cardiovascular 265 (36)
Respiratory 320 (44)
Neoplasic 86 (12)
Diabetes mellitus 67 (9)
Alcoholism 113 (15)
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Variables Hazard ratio 95% CI P-value
Mountain’s stage IIIb–IV 2.46 [1.90–3.18] o0.001
Simplified comorbidity score 1.36 [1.09–1.69] 0.006
Weight loss more than 5% 1.39 [1.12–1.73] 0.003
Poor Performance Status 1.33 [0.99–1.76] 0.050
Age 470 years 1.23 [0.98–1.54] 0.080
Leucocytes 410000ml
 1 1.23 [0.99–1.52] 0.060
Table 5 Step 2, Charlson comorbidity index (CCI) vs simplified
comorbidity score (SCS): classification of comorbididy conditions by both
scales (k coefficient of reliability¼0.288; Po0.00001; McNemar test of
symmetry; P¼0.0008)
SCS
CCI 0–7 8–9 10–11 X12 Total
02 4 721 3 4
1–2 11 35 3 16 65
3–4 2 9 5 13 29
X501 4 3 8
Total 37 52 14 33 136
Table 3 Step 1, univariate analysis
Variable
Median survival
(months) [95% CI]
P
(log-rank)
Age (years)
p70 14 [12.4–16] o0.01
470 9.6 [8.8–12]
Gender
Female 16.2 [13.9–21.6] 0.03
Male 11.7 [10.3–13.3]
ECOG performance status
o2 14.1 [12.7–15.7] o0.01
X2 6.7 [4.3–8.1]
T-stage
1–2 18.5 [14.8–21.8] o0.01
3–4 10.4 [9.6–12.3]
N-stage
0–1 16.3 [14–20] o0.01
2–3 10.6 [9.6–12.3]
M-stage
0 18.2 [15.7–21.6] o0.01
1 8.8 [7.8–10]
Stage grouping
I–IIIa 24.7 [20.3–27.5] o0.01
IIIb–IV 10.2 [9.4–11.5]
Histology
Adenocarcinoma 14 [11.3–16.2] 0.31
Nonadenocarcinomatous 11.8 [10.3–13.5]
Weight loss
o5% 16.5 [13.9–18.5] o0.01
X5% 8.7 [7.2–10.4]
Blood leucocyte count
p10 10
9l
 1 14.7 [12.8–17] o0.01
410 10
9l
 1 10.4 [9.5–13.2]
Blood platelets count
p400 10
9l
 1 13.5 [12.1–15] 0.03
4400 10
9l
 1 9.9 [8.7–14]
Smoking status
Smoker 12.3 [10.9–13.8] 0.04
Nonsmoker 16.2 [13.3–24.3]
Cardiovascular comorbidities
Yes 13.2 [11.4–14.8] 0.62
No 11.7 [9.8–14.4]
Respiratory comorbidities
Yes 13 [10.8–14.9] 0.16
No 12.4 [10.5–14.2]
Neoplasic comorbidities
Yes 12.9 [11.3–14.1] 0.96
No 12 [9.7–18.2]
Diabetes mellitus
Yes 12.9 [11.3–14.1] 0.08
No 10.3 [7.4–15]
Renal insufficiency
Yes 13.8 [12.4–15.7] 0.02
No 10.4 [9–14.2]
Alcoholism
Yes 13.3 [11.3–14.6] 0.07
No 10.4 [8.4–13.8]
Simplified comorbidity score
p9 14.7 [13–16.9] o0.01
49 9.9 [8.6–13.2]
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Figure 1 Step 2 patients survival according to SCS (log rank test;
Po0.01).
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Figure 2 Step 2 patients survival according to CCI (log rank test;
P¼0.06).
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result of redundancy of the prognostic information.
DISCUSSION
In the score generation part of this study (step 1), we evaluated the
prognosis of a large NSCLC population accrued during a 5-year
period, simultaneously assessing different aforementioned comor-
bidities together with classical prognostic determinants. The
threshold value for this new score has been chosen taking into
account a clear cutoff effect within and beyond the value 9
according to univariate analysis. The 1- and 2-year survival rates
were 51 and 29%, respectively, with a median survival of the whole
population of 12.7 months, which is consistent with NSCLC
population survival curves. In the multivariate analysis, several
characteristics were identified as independent poor prognosis
variables: poor performance status, weight loss equal to or greater
than 5%, stage equal to or greater than IIIb and SCS greater than 9.
The first three are well-identified NSCLC features strongly
indicating prognosis (Stanley, 1980; Paesmans et al, 1995). The
main goal of the step 1 part of this study was to generate a simple
comorbidity index, which may add new information to the
prognostic patient equation. In the score validation part of this
study (step 2), the SCS was tested in two ways: (i) by evaluating
this new score together with a wide panel of prognostic variables
including biological ones that were not exhaustively assessed in
step 1, and (ii) by comparing SCS and CCI, the latter having been
extensively applied to different malignant diseases including lung
cancer (Firat et al, 2002a,b; Pergolizzi et al, 2002; Birim et al,
2003a,b; Ludbrook et al, 2003; Tammemagi et al, 2003). Both
criteria were reached demonstrating the validity of the variables as
a prognostic determinant.
The OncoLR heath network is devoted to cancer therapy and
accrued all patients affected by lung cancer without other eligibility
restriction than those defined in the Pateints and Method section,
that is, histologically proven and previously untreated NSCLC.
Physicians participating in the OncoLR heath network are mainly
oncologists and chest physicians involved in cancer care. There-
Table 6 Step 2 patients’ demography, disease characteristics and
univariate analysis
Variable Number
Median survival
(months)
[95% CI]
P
(log-rank)
Total 136
Age (years, median7s.d.)
62.5711.2
Age (years)
p70 92 (67.6) NR [12.3–NR] 0.05
470 44 (32.4) 11.3 [6.0–NR]
Gender
Female 29 (21.3) NR [NR–NR] 0.44
Male 107 (78.7) NR [11–NR]
ECOG performance status
o2 105 (77.2) NR [12.3–NR] o0.01
X2 31 (22.8) 6.3 [4.9–NR]
Stage grouping
I–IIIa 52 (38.5) NR [NR–NR] o0.01
IIIb–IV 84 (61.5) 10.1 [6.4–NR]
Histology
Adenocarcinoma 58 (42.6) NR [NR–NR] o0.01
Nonadenocarcinomatous 78 (57.4) 11.3 [7.8–NR]
Weight loss
o5% 77 (56.6) NR [NR–NR] 0.02
X5% 59 (43.4) 11.3 [7.3–NR]
Blood leucocyte count
p10.10
9l
 1 86 (63.2) NR [NR–NR] o0.01
410.10
9l
 1 50 (37.8) 7.9 [4.9–NR]
Haemoglobin level
p11gdl
 1 20 (14.7) 6.4 [2.9–10.3] o0.01
411dl
 1 116 (85.3) NR [12.3–NR]
Blood lymphocyte count
X10
9l
 1 118 (86.8) NR [NR–NR] o0.01
o10
9l
 1 13 (9.6) 4.4 [2.0–12.3]
Blood platelets count
p400.10
9l
 1 109 (80.1) NR [12.3–NR] 0.08
4400.10
9l
 1 27 (19.9) 10.3 [6.0–NR]
CCI
o3 99 (72.8) NR [12.3–NR] 0.06
X3 37 (27.2) 10.3 [5.4–NR]
SCS
p9 89 (65.4) NR [NR–NR] o0.01
49 47 (34.6) 10.1 [5.4–NR]
Serum fibrinogen level
Normal 41 (30.1) NR [NR–NR] o0.01
Increased 86 (69.9) 11.3 [7.8–NR]
Serum calcium level
Normal 130 (97.1) NR [12.3–NR] 0.02
Increased 4 (2.9) 5.2 [0.1–NR]
Serum sodium level
Normal 122 (89.7) NR [12.3–NR] 0.09
Lowered 14 (10.3) 7.2 [2.1–NR]
Alkaline phosphatases
Normal 97 (71.3) NR [NR–NR] o0.01
Increased 36 (26.5) 7.4 [4.9–NR]
Table 6 (Continued)
Variable Number
Median survival
(months)
[95% CI]
P
(log-rank)
LDH
Normal 104 (76.5) NR [NR–NR] o0.01
Increased 28 (20.6) 5.9 [4.4–NR]
Serum protein level
p64gl
 1 10 (7.4) NR [NR–NR] o0.01
464gl
 1 125 (91.9) 4.2 [1.1–12.3]
Serum albumin level
o35gl
 1 18 (13.2) 5.9 [2.7–NR] o0.01
X35gl
 1 115 (84.6) NR [12.3–NR]
Serum Cyfra 21–1 level
o3.6ngml
 1 73 (53.7) NR [NR–NR] o0.01
X3.6ngml
 1 58 (42.6) 7.4 [6.3–NR]
Serum NSE level
p12.5ngml
 1 83 (61.0) NR [12.3–NR] 0.01
412.5ngml
 1 38 (27.9) 7.4 [5.4–NR]
CCI: Charlson comorbidity index; ECOG: Eastern Cooperative Oncology Group;
LDH: lactate dehydrogenase; NR: not reached; NSE: neuron-specific enolase; SCS:
simplified comorbidity score; s.d.: standard deviation.
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presentation were refereed to other institutions such as palliative
care units. Nevertheless, we consider that our population is more
representative of overall lung cancer population than are for
example populations included in clinical trials.
Comorbid conditions are frequent in NSCLC patient popula-
tions, considering the mean age and the high frequency of smokers
of this population. Comorbidities are considered as an important
prognostic factor in patients with different types of cancer,
including lung cancer (Feinstein et al, 1977; Wells et al, 1984;
Clemens et al, 1986; Feinstein and Wells, 1990; Miller et al, 1992;
Waldman and Potter, 1992; Piccirillo et al, 1994; Satariano and
Ragland, 1994; Piccirillo and Feinstein, 1996; Rochon et al, 1996;
Pugliano et al, 1997; Singh et al, 1997; Extermann et al, 1998; Firat
et al, 2002a). Comorbidities may impair survival by themselves or
by affecting the therapeutic options. For example, the 5-year
survival rate for the rectum (Feinstein et al, 1975), larynx
(Feinstein et al, 1977), endometrial (Wells et al, 1984) or prostate
(Clemens et al, 1986) carcinomas differs when a prognostic
comorbidity is present (11, 15, 27, and 16%, respectively) or absent
(32, 54, 78 and 60%). In our study, a high frequency of
comorbidities has been found especially for respiratory and
cardiovascular diseases, closely associated with smoking status.
These results are consistent with other unselected series of lung
cancer. For example, in a multicentre study of 2992 patients
affected by an operable NSCLC, 73% presented with one or several
of the tested comorbidities and 50% presented with an associated
COPD (Lopez-Encuentra, 2002). Other experiences report comor-
bidity frequencies of up to 61% on 442 newly diagnosed cases of
lung cancer (Schrijvers et al, 1997).
Age is generally considered as a negative prognostic factor,
whatever the treatment modality (Stanley, 1980; Williams et al,
1981; Paesmans et al, 1995). However, there is no consensus
regarding the threshold that might be used in order to define
an elderly population. Ages varying from 60 to 70 years have
been reported. In addition, there is a lack of epidemiological
data concerning prognostic factors in the elderly NSCLC patient
populations. In our study, age 470 years was associated
with a worse outcome, reaching statistical significance in an
univariate analysis. It is worth noting that this variable did not
reach conventional statistical significance in the multivariate
analysis suggesting that there is redundancy of the herein SCS
and age.
Comorbid conditions have been evaluated using several clinical
scores from longitudinal studies. The most widely used clinical
score is the CCI, developed by Charlson et al (1987). This index has
been validated in a cohort of breast cancer patients (Charlson et al,
1987), giving a method of measuring the prognostic impact of
comorbid disease. Since this initial publication, the CCI has been
validated and used in several cancer studies (head and neck (Singh
et al, 1997), stomach (Lubke et al, 2003), bladder (Miller et al,
2003), kidney (Gettman et al, 2003), prostate (Froehner et al,
2003)) including lung cancer (Firat et al, 2002a; Birim et al, 2003a)
and cancer in the elderly (Extermann et al, 1998). In our study, we
developed and validated a new SCS. This score considers tobacco
consumption together with clinical comorbid conditions (diabetes
mellitus, renal insufficiency, respiratory, neoplasic and cardiovas-
cular comorbidities) and alcoholism. An SCS greater than 9 was
found to be an independent prognostic factor of poor outcome.
This score has been developed for a large, unselected NSCLC
population. An advantage of SCS over standard comorbidity scores
including CCI is the reduced number of items taken into account
allowing score calculation in only a few minutes. As not all
comorbidities assessed in the CCI were checked in the SCS, we
considered that there was a need for direct comparison of the SCS
and the CCI in the same population. This evaluation was formally
carried out in the score evaluation part of the study. In this second
population, the SCS was validated as an independent prognostic
determinant and appears more informative than the CCI in
predicting patient outcome in the setting of NSCLC patients.
In conclusion, the SCS, constructed as an independent prog-
nostic factor in a large NSCLC patient population, is validated in
another prospective population and appears more informative
than the CCI in predicting patient outcome. The amalgamation of
this new prognostic score into the set of classical prognostic
determinants might be useful when prognostic studies are
evaluated. SCS could also be considered as a part of the
pretherapeutic work-up of clinical trials. The Cox model result
of the second step is a clue in favour of the independent negative
prognostic effect of poor comorbidity score. This result deserves
further studies designed to determine whether or not this finding
has clinical impact in treatment algorithms.
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